Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.

S, Takahashi; M, Karayama; M, Takahashi; J, Watanabe; H, Minami; N, Yamamoto; I, Kinoshita; CC, Lin; YH, Im; I, Achiwa; E, Kamiyama; Y, Okuda; C, Lee; YJ, Bang

doi:10.1158/1078-0432.ccr-21-1560

Public

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.

Shared by NobleBlocks on Aug 23, 2021 • 12:00 AM UTC

Authors:

Takahashi S

Karayama M

Takahashi M

Abstract

<h4>Purpose</h4>To evaluate drug-drug interactions between the human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd; DS-8201a) and the OATP1B/CYP3A inhibitor ritonavir or the strong CYP3A inhibitor itraconazole.<h4>Patients and methods</h4>Pa...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!